January 13, 2025 - 02:56
ALAMEDA, Calif., January 12, 2025—Exelixis, Inc. has announced its preliminary unaudited financial results for the fiscal year 2024, alongside financial guidance for the upcoming fiscal year 2025. The company is optimistic about the potential for significant advancements in clinical and regulatory efforts, particularly concerning its cabozantinib franchise.
In 2025, Exelixis plans to focus on executing its clinical programs and anticipates multiple data readouts for zanzalintinib, as well as developments across its diverse pipeline of small molecules and biotherapeutics. The company aims to leverage its existing assets while exploring new opportunities to enhance its market position.
With a clear strategy in place, Exelixis is poised for a year of growth, innovation, and impactful milestones that could shape the future of its therapeutic offerings. The commitment to advancing patient care remains at the forefront of Exelixis's mission as it navigates the challenges and opportunities ahead.
